Literature for danoprevir (S29.001 inhibitor)

(Topics flags: S Structure, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2018
1. Matthew,A.N., Leidner,F., Newton,A., Petropoulos,C.J., Huang,W., Ali,A., KurtYilmaz,N. and Schiffer,C.A.
   Molecular mechanism of resistance in a clinically significant double-mutant variant of HCV NS3/4A protease
   Structure26, 1360-1372. PubMed  Europe PubMed DOI  I
2016
2. Meeprasert,A., Hannongbua,S., Kungwan,N. and Rungrotmongkol,T.
   Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir
   Mol Biosyst12, 3666-3673. PubMed  Europe PubMed DOI  I
2014
3. Meeprasert,A., Hannongbua,S. and Rungrotmongkol,T.
   Key binding and susceptibility of NS3/4A serine protease inhibitors against hepatitis C virus
   J Chem Inf Model54, 1208-1217. PubMed  Europe PubMed DOI  I
2013
4. Ali,A., Aydin,C., Gildemeister,R., Romano,K.P., Cao,H., Ozen,A., Soumana,D., Newton,A., Petropoulos,C.J., Huang,W. and Schiffer,C.A.
   Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance
   ACS Chem Biol8, 1469-1478. PubMed  Europe PubMed DOI  I
2012
5. Lim,S.R., Qin,X., Susser,S., Nicholas,J.B., Lange,C., Herrmann,E., Hong,J., Arfsten,A., Hooi,L., Bradford,W., Najera,I., Smith,P., Zeuzem,S., Kossen,K., Sarrazin,C. and Seiwert,S.D.
   Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution
   Antimicrob Agents Chemother56, 271-279. PubMed  Europe PubMed DOI  I
6. Romano,K.P., Ali,A., Aydin,C., Soumana,D., Ozen,A., Deveau,L.M., Silver,C., Cao,H., Newton,A., Petropoulos,C.J., Huang,W. and Schiffer,C.A.
   The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
   PLoS Pathog8, e1002832-e1002832. PubMed  Europe PubMed DOI  S  I
2011
7. Fusco,D.N. and Chung,R.T.
   New protease inhibitors for HCV - help is on the way
   J Hepatol54, 1087-1089. PubMed  Europe PubMed DOI  I
8. Gottwein,J.M., Scheel,T.K., Jensen,T.B., Ghanem,L. and Bukh,J.
   Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses
   Gastroenterology141, 1067-1079. PubMed  Europe PubMed DOI  I
9. Schaefer,C.J., Kossen,K., Lim,S.R., Lin,J.H., Pan,L., Bradford,W., Smith,P.F. and Seiwert,S.D.
   Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection
   Antimicrob Agents Chemother55, 3125-3132. PubMed  Europe PubMed DOI  I
2010
10. Bae,A., Sun,S.C., Qi,X., Chen,X., Ku,K., Worth,A., Wong,K.A., Harris,J., Miller,M.D. and Mo,H.
    Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors
    Antimicrob Agents Chemother54, 5288-5297. PubMed  Europe PubMed DOI  I
11. Deutsch,M. and Papatheodoridis,G.V.
    Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection
    Curr Opin Investig Drugs11, 951-963. PubMed  Europe PubMed  I
2009
12. Rajagopalan,R., Misialek,S., Stevens,S.K., Myszka,D.G., Brandhuber,B.J., Ballard,J.A., Andrews,S.W., Seiwert,S.D. and Kossen,K.
    Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior
    Biochemistry48, 2559-2568. PubMed  Europe PubMed DOI  I
2008
13. Seiwert,S.D., Andrews,S.W., Jiang,Y., Serebryany,V., Tan,H., Kossen,K., Rajagopalan,P.T., Misialek,S., Stevens,S.K., Stoycheva,A., Hong,J., Lim,S.R., Qin,X., Rieger,R., Condroski,K.R., Zhang,H., Do,M.G., Lemieux,C., Hingorani,G.P., Hartley,D.P., Josey,J.A., Pan,L., Beigelman,L. and Blatt,L.M.
    Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227)
    Antimicrobial Agents Chemother52, 4432-4441. PubMed  Europe PubMed DOI  I